A call to rethink the necessity of and challenges facing academic research organizations in the new era of drug innovation in China

The objectives of drug R&D in China have shifted toward innovation and globalization, highlighting the ecological imperative to involve innovative partner-like academic research organizations (AROs). AROs are led by academic institutions and, when compared to contract research organizations (CROs), their strengths lie in promoting academic excellence, knowledge sharing, independence, collaborative networks and industry partnerships. Our desk-based analysis shows that although the service scope of Chinese AROs is similar to that of AROs in the US, they lack experience in broad service provision for innovative drugs, institution-institutional platforms and industry partnerships. We make several suggestions about how to achieve the synergy of academic institutions and industry-based organizations in drug innovation by using a ARO-CRO hybrid service model.

Tax credits for pharmaceutical research, development and marketing?

BACKGROUND

The pharmaceutical industry is believed to receive considerable support through research and development (R&D) tax credits.

OBJECTIVE

The objectives of this paper are (a) to show that many of the pharmaceutical industry's apparent R&D activities are entangled with marketing efforts, and (b) to argue that supporting these activities through tax credits does not serve public interests in health.

METHODS

The bulk of this paper summarizes the author's extended qualitative mixed-methods approach to following connections between pharmaceutical research and marketing.

RESULTS

The pharmaceutical industry's R&D should be understood as broadly entangled with marketing, and so generally should be understood as integrated research, development and marketing (RD&M).

CONCLUSIONS

R&D tax credits to the pharmaceutical industry largely do not serve public interests.

Does environmental and renewable energy R&D help to achieve carbon neutrality target? A case of the US economy

The current study investigates carbon neutrality targets for the US's case while analyzing the role of environmental-related research and development (ERR&D) and renewable energy research and development (RER&D). This study also considered economic growth (GDP) and energy productivity (EP) as controlled variables. Utilizing the time series data over the period from 1990 to 2019, this study used various econometric approaches, such as unit root tests and cointegration tests for stationarity and the long-run association between variables, respectively. This study's main econometric regression tools, such as dynamic ordinary least square (DOLS) and fully modified ordinary least square (FMOLS), are utilized. The empirical findings reveal that economic growth played a negative role in achieving carbon neutrality targets. However, EP, RER&D, and ERR&D positively contribute to carbon neutrality target achievement by reducing atmospheric CO₂ emissions. Moreover, this study found a cointegration relationship between the study variables. The bidirectional causality is found between ERR&D and CO₂ emissions, while a unidirectional causality is observed, running from exogenous variables towards CO₂ emissions. Based on the empirical findings, this study recommends expanding the investment and expenditures in both ERR&D and RER&D sectors to attain carbon neutrality.

Current status and future prospects for ion-mobility mass spectrometry in the biopharmaceutical industry

Detailed characterization of protein reagents and biopharmaceuticals is key in defining successful drug discovery campaigns, aimed at bringing molecules through different discovery stages up to development and commercialization. There are many challenges in this process, with complex and detailed analyses playing paramount roles in modern industry. Mass spectrometry (MS) has become an essential tool for characterization of proteins ever since the onset of soft ionization techniques and has taken the lead in quality assessment of biopharmaceutical molecules, and protein reagents, used in the drug discovery pipeline. MS use spans from identification of correct sequences, to intact molecule analyses, protein complexes and more recently epitope and paratope identification. MS toolkits could be incredibly diverse and with ever evolving instrumentation, increasingly novel MS-based techniques are becoming indispensable tools in the biopharmaceutical industry. Here we discuss application of Ion Mobility MS (IMMS) in an industrial setting, and what the current applications and outlook are for making IMMS more mainstream.

Systematic risk identification and assessment using a new risk map in pharmaceutical R&D

Delivering transformative therapies to patients while maintaining growth in the pharmaceutical industry requires an efficient use of research and development (R&D) resources and technologies to develop high-impact new molecular entities (NMEs). However, increasing global R&D competition in the pharmaceutical industry, growing impact of generics and biosimilars, more stringent regulatory requirements, as well as cost-constrained reimbursement frameworks challenge current business models of leading pharmaceutical companies. Big data-based analytics and artificial intelligence (AI) approaches have disrupted various industries and are having an increasing impact in the biopharmaceutical industry, with the promise to improve and accelerate biopharmaceutical R&D processes. Here, we systematically analyze, identify, assess, and categorize key risks across the drug discovery and development value chain using a new risk map approach, providing a comprehensive risk-reward analysis for pharmaceutical R&D.

Global health landscape challenges triggered by COVID-19

The COVID-19 pandemic highlighted the vulnerability of every aspect of the globalized world, including R&D. Potentially critical R&D areas have been neglected because of the lack of market-driven incentives. However, new initiatives are emerging to address the present crisis of COVID-19 and possibly future similar incidents that will threaten humanity. In this paper, the global health landscape of R&D is discussed in terms of research focus and funding, illustrating under-funding in communicable diseases with the exception of three major infections: HIV/AIDS, tuberculosis, and malaria. The initiatives triggered by the COVID-19 pandemic and the novel emphasis on "access" are discussed. Finally, the authors propose a new funding model to address R&D in the case of market failure, by forming alliance between government, industry, and international philanthropic organization (GHIT model), and define clear strategy of enhancing access as the way forward.

Digital Twins: A General Overview of the Biopharma Industry

This chapter gives an industry perspective of how digital twins are tangibly translated, implemented, and used in a biopharmaceutical environment. Technical prerequisites and components including data modeling, the lifecycle, and different skills which are required from people to be put together and collaborate efficiently with digital twins are discussed with practical examples which have been implemented in labs and in manufacturing.